Matthew J. Frank

Oncology

500 Pasteur Dr
Palo Alto, CA 94304

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.

Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.

Journal: American journal of hematology

Published: January 08, 2026

Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.

Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.

Journal: Leukemia & lymphoma

Published: December 26, 2025

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.

Journal: Research square

Published: November 24, 2025

Superior Chronic Graft-versus-Host Disease-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.

Superior Chronic Graft-versus-Host Disease-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: November 18, 2025

Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.

Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.

Journal: Blood advances

Published: November 13, 2025

Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS.

Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS.

Journal: Blood advances

Published: November 13, 2025

How I treat HLH-like toxicities after immune effector cell therapy.

How I treat HLH-like toxicities after immune effector cell therapy.

Journal: Blood

Published: November 07, 2025

Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].

Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].

Journal: Transplantation and cellular therapy

Published: October 09, 2025

Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.

Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.

Journal: Blood cancer journal

Published: August 16, 2025

Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.

Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.

Journal: Blood cancer discovery

Published: July 15, 2025

Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.

Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.

Journal: Blood cancer discovery

Published: July 15, 2025

Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies.

Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies.

Journal: Cytotherapy

Published: May 06, 2025

Showing 1-12 of 61

Last Updated: 09/26/2026